Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NJ5H
|
|||
| Former ID |
DCL000421
|
|||
| Drug Name |
Alogliptin
|
|||
| Synonyms |
850649-61-5; UNII-JHC049LO86; alogliptina; 2-({6-[(3r)-3-Aminopiperidin-1-Yl]-3-Methyl-2,4-Dioxo-3,4-Dihydropyrimidin-1(2h)-Yl}methyl)benzonitrile; SYR-322; JHC049LO86; (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile; CHEBI:72323; AK322010; 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile; vipidia; Alogliptin [INN]; Alogliptin (SYR-322); alogliptinum; alogliptine; HSDB 8203; UNII-JHC049LO86
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Approved | [1], [2], [3] | |
| Company |
Takeda
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H21N5O2
|
|||
| Canonical SMILES |
CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCCC(C3)N
|
|||
| InChI |
1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
|
|||
| InChIKey |
ZSBOMTDTBDDKMP-OAHLLOKOSA-N
|
|||
| CAS Number |
CAS 850649-61-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16549582, 23591487, 42529629, 46516529, 57376680, 79634689, 87544227, 93300285, 103516453, 126665588, 134339050, 135207592, 137147468, 140812881, 160962873, 162009811, 162253849, 164193948, 164835224, 175265639, 175427056, 178102937, 185988964, 210279140, 210281462, 223574691, 223683116, 224085697, 226492557, 241154940, 244648029, 249810610, 251971115, 252214702, 252553765, 252671739
|
|||
| ChEBI ID |
CHEBI:72323
|
|||
| ADReCS Drug ID | BADD_D00079 ; BADD_D00080 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dipeptidyl peptidase 4 (DPP-4) | Target Info | Inhibitor | [4], [5], [6] |
| KEGG Pathway | Protein digestion and absorption | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6319). | |||
| REF 2 | Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of Takeda (2009). | |||
| REF 5 | Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db... Br J Pharmacol. 2009 Jun;157(3):415-26. | |||
| REF 6 | Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.